title: Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
authors: Division of Cancer Neurology, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. mchheda@partners.org
authors: M G
authors: MG
authors: Chheda
authors: J
authors: J
authors: Drappatz
authors: N J
authors: NJ
authors: Greenberger
authors: S
authors: S
authors: Kesari
authors: S E
authors: SE
authors: Weiss
authors: D C
authors: DC
authors: Gigas
authors: L M
authors: LM
authors: Doherty
authors: P Y
authors: PY
authors: Wen
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005909:Glioblastoma / Q000188:drug therapy*; D006509:Hepatitis B / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D019259:Lamivudine / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000503:physiopathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D013125:Spinal Neoplasms / Q000556:secondary* / Q000628:therapy; D000077204:Temozolomide; D016896:Treatment Outcome; D019562:Viral Load; D014775:Virus Activation / Q000187:drug effects / Q000235:genetics
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D003606:Dacarbazine; D000077204:Temozolomide